For the quarter ending 2025-09-30, VTYX had -$331K decrease in cash & cash equivalents over the period. -$17,558K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expenses | 84,304 | - |
| Loss from operations | -84,304 | - |
| Interest income | 7,088 | - |
| Other expense | -40 | - |
| Total other (income) expense | 7,048 | - |
| Net loss | -22,829 | -54,427 |
| Depreciation | 58 | 161 |
| Amortization of right-of-use assets - operating | 268 | 518 |
| Stock-based compensation | 4,601 | 9,606 |
| Accretion of marketable securities, net | -1,063 | -2,907 |
| Prepaid expenses and other assets | -1,943 | -1,988 |
| Operating lease liabilities | -270 | -500 |
| Accounts payable | 101 | -2,236 |
| Accrued expenses | -317 | 802 |
| Net cash used in operating activities | -17,508 | -46,995 |
| Purchases of marketable securities, available-for-sale | 34,774 | 53,348 |
| Proceeds from maturities of marketable securities, available-for-sale | 51,875 | 105,013 |
| Purchases of property and equipment | 50 | 58 |
| Net cash provided by (used in) investing activities | 17,051 | 51,607 |
| Proceeds from exercise of stock options | 203 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 68 |
| Net cash provided by financing activities | 203 | 68 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -77 | 361 |
| Net increase in cash, cash equivalents and restricted cash | -331 | 5,041 |
| Cash and cash equivalents at beginning of period | 28,235 | - |
| Cash and cash equivalents at end of period | 32,945 | - |
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. (VTYX)